- PROFESSOR Anesthesiology
- PROFESSOR Obstetrics, Gynecology and Reproductive Science
American Board of Anesthesiology
MD, Mount Sinai School of Medicine
Residency, Internal Medicine
Maimonides Medical Center
Mount Sinai Hospital
Beilin Y, Friedman, Jr F, Andres LA, Hossain S, Bodian CA. The effect of the obstetrician group and epidural analgesia on the risk for cesarean delivery in nulliparous women. Acta Anaesthesiol Scand 2000 Sep; 44(8): 959-964.
Beilin Y, Leibowitz AB, Bernstein HH, Abramovitz SE. Controversies of labor epidural analgesia. Anesth Analg 1999 Oct 89:969.
Abramovitz SE, Beilin Y. Anesthetic management of the parturient with protein S deficiency and ischemic heart disease. Anesth Analg 1999 Sep;89(3):709-10 1999 Sep; 89(3): 709-10.
Beilin Y, Galea M, Zahn J, Bodian C. Epidural ropivacaine for the initiation of labor epidural analgesia: a dose finding study. Anesth Analg 1999 Jun; 88(6): 1340-5.The purpose of our study was to determine the lowest concentration of ropivacaine that offers pain relief for the initiation of labor epidural analgesia. Women in active labor were enrolled in this prospective, randomized, double-blinded study to receive either ropivacaine 0.20% (Group I), ropivacaine 0.15% (Group II), or ropivacaine 0.10% (Group III). After placement of the epidural catheter, 13 mL of the study medication was administered. Fifteen minutes later, the adequacy of analgesia was assessed. If the woman reported that her degree of analgesia was not adequate, an additional 5 mL of the study medication was given, the degree of pain relief was reassessed 15 min later, and the study was concluded. A sequential study design was used to assess the success rates. We found that 26 of 28 (93%) women in Group I had adequate analgesia, compared with only 18 of 28 (64%) in Group II (P = 0.014) and 4 of 12 (33%) in Group III (P = 0.003). We conclude that ropivacaine 0.20% offers adequate analgesia significantly more often than either ropivacaine 0.15% or ropivacaine 0.10%. If one selects ropivacaine as the sole local anesthetic for the initiation of labor epidural analgesia, the minimal concentration should be 0.20%. IMPLICATIONS: The lowest effective concentration of ropivacaine for the initiation of labor epidural analgesia has not been determined. We found that ropivacaine 0.20% offers adequate analgesia significantly more often than either ropivacaine 0.15% or ropivacaine 0.10%. If one selects ropivacaine as the sole local anesthetic for the initiation of labor epidural analgesia, the minimal concentration should be 0.20%.
Beilin Y, Bodian C, Mukherjee T, Andres L, Vincent RD, Hock DL, Sparks AE, Munson AK, Minnich ME, Steinkampf MP, Christman GM, McKay RS, Eisenkraft J. The use of propofol, nitrous oxide, or isoflurane does not affect the reproductive success rate following gamete intrafallopian transfer (GIFT): a mul. Anesthesiology 1999 Jan; 90(1): 36-41.BACKGROUND: Whether anesthetic agents administered during gamete intrafallopian transfer (GIFT) affect reproductive outcome is controversial. This multicenter pilot trial and survey had two purposes: to evaluate the effect of propofol, nitrous oxide, midazolam, and isoflurane on pregnancy outcome after GIFT, and to determine if a larger prospective, randomized study is warranted. METHODS: A written invitation was mailed to all 50 fertility programs in the United States that are members of the Society for Assisted Reproductive Technology and perform more than 30 GIFT procedures per year. They were invited to contribute information from the medical records of women who underwent GIFT during the calendar years 1993 and 1994. They were asked to document whether propofol, nitrous oxide, midazolam, a potent inhaled anesthetic agent was used during the GIFT procedure; if the woman became pregnant; and if she delivered at least one live neonate. RESULTS: Seven medical centers participated and contributed data from 455 women. The clinical pregnancy rate (number of pregnancies/total number of GIFT procedures) and the delivery rate (number of women who delivered at least one live baby/total number of GIFT procedures) were 35% and 32%, respectively. A statistically significant difference could not be found in the clinical pregnancy or delivery rates between those women who received propofol, nitrous oxide, midazolam, or isoflurane during GIFT and those who did not. CONCLUSIONS: No agent-related differences in pregnancy rates were found when propofol, nitrous oxide, isoflurane, or midazolam was used as part of the anesthetic technique for GIFT. Therefore, a more extensive prospective trial does not appear to be warranted.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Beilin did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Klingenstein Clinical Center Floor Dept of Anesthesiology Room 8th Floor Room 8-32
1450 Madison Avenue
New York, NY 10029
Faculty Practice Associates
GPO Box 12023
Newark, NJ 07101
- 1199 National Benefit Fund
- Aetna U.S. Healthcare
- CIGNA - Indemnity
- CIGNA Healthcare HMO
- CenterCare, Inc.
- Health Insurance Plan (HIP)
- HealthFirst/Medicaid HMO
- Oxford Health Plans
- Private Healthcare Systems (PHCS)
- United Healthcare
- Master Card
- American Express
- Personal Check